Allspring Global Investments Holdings LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Allspring Global Investments Holdings LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,217 shares of the biopharmaceutical company’s stock after buying an additional 5,918 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.05% of Regeneron Pharmaceuticals worth $56,034,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Eudaimonia Advisors LLC raised its stake in Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 11 shares during the period. Drive Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. LCM Capital Management Inc increased its holdings in Regeneron Pharmaceuticals by 2.5% in the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after purchasing an additional 12 shares in the last quarter. Finally, TrinityPoint Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on REGN. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,027.55.

Insiders Place Their Bets

In related news, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders sold a total of 63,208 shares of company stock worth $62,514,142 over the last ninety days. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $1,044.66 on Wednesday. The stock has a market cap of $115.11 billion, a price-to-earnings ratio of 30.86, a PEG ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. Regeneron Pharmaceuticals, Inc. has a 12 month low of $688.52 and a 12 month high of $1,081.17. The stock’s 50 day moving average price is $987.40 and its 200 day moving average price is $952.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.